NCT01859962View on ClinicalTrials.gov

Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

December 31, 2014

Conditions
Chronic Hepatitis C
Interventions
DRUG

PPI-668

DRUG

BI 207127 Dose 1

DRUG

BI 207127 Dose 2

DRUG

Faldaprevir

DRUG

Ribavirin

DRUG

BI 207127 Placebo

Trial Locations (1)

94115

Quest Clinical Research, San Francisco

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Presidio Pharmaceuticals, Inc.

INDUSTRY

NCT01859962 - Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C | Biotech Hunter | Biotech Hunter